PRME
Prime Medicine, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$590.62M
P/E Ratio
—
EPS
$-1.23
Beta
2.36
52W High
$6.94
52W Low
$1.11
50-Day MA
$3.60
200-Day MA
$4.02
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Prime Medicine, Inc. Common Stock
Prime Medicine, Inc. is a forefront biotechnology company innovating in genetic medicine through its proprietary Prime Editing technology, which allows for precise DNA modifications. With a robust pipeline focused on addressing severe diseases, including genetic disorders and various cancers, the company is well-positioned to tackle substantial unmet medical needs. Supported by strong intellectual property assets, Prime Medicine is poised to be a significant contributor to the biopharmaceutical industry, offering promising growth opportunities and transformative solutions that could redefine treatment paradigms.
Fundamentals
| Revenue (TTM) | $4.03M |
| Gross Profit (TTM) | $-150.14M |
| EBITDA | $-199.14M |
| Operating Margin | -5918.00% |
| Return on Equity | -216.10% |
| Return on Assets | -41.50% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.68 |
| Price-to-Book | 7.56 |
| Price-to-Sales (TTM) | 146.41 |
| EV/Revenue | 138.52 |
| EV/EBITDA | -3.10 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -41.10% |
| Shares Outstanding | $180.62M |
| Float | $107.33M |
| % Insiders | 23.76% |
| % Institutions | 65.55% |
Historical Volatility
HV 10-Day
56.55%
HV 20-Day
51.62%
HV 30-Day
50.68%
HV 60-Day
67.76%
HV Rank
0.0%
Volatility is currently expanding
Analyst Ratings
Consensus ($6.92 target)
1
Strong Buy8
Buy4
HoldMore HEALTHCARE Stocks
Data last updated: 5/14/2026